Literature DB >> 1690156

The jejunal secretion of histamine is increased in active Crohn's disease.

L Knutson1, O Ahrenstedt, B Odlind, R Hällgren.   

Abstract

Previous studies of mast-cell density and histamine content in biopsy specimens in patients with Crohn's disease have yielded conflicting results. In this in vivo study we have measured the jejunal secretion rate of histamine in patients with Crohn's disease (n = 15) of the terminal small bowel and in healthy controls (n = 24). The secretion studies were performed using a recently developed segmental jejunal perfusion system with a two-balloon, six-channel small tube. The histamine secretion rate was 152 +/- 29 (SEM) ng/cm small intestine per h in patients with Crohn's disease, which meant a significant increase (p less than 0.01) compared with the secretion rate in controls (71 +/- 11 ng/cm per h). Moreover, the secretion of histamine was related to the disease activity. Patients with active disease (n = 8) (i.e., Crohn's disease activity index greater than 150) had a mean histamine secretion rate of 193 +/- 47 ng/cm per h, while patients with inactive disease (Crohn's disease activity index less than 150) had a secretion rate not significantly increased compared with controls (105 +/- 24 ng/cm per h). The present data indicate increased mast-cell involvement of the small intestine in active Crohn's disease of the distal ileum. This finding might reflect the systemic nature of the disease process.

Entities:  

Mesh:

Year:  1990        PMID: 1690156     DOI: 10.1016/0016-5085(90)90006-m

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  32 in total

1.  Mesenteric blood flow is related to disease activity and risk of relapse in ulcerative colitis: a prospective follow up study.

Authors:  D Ludwig; S Wiener; A Brüning; K Schwarting; G Jantschek; K Fellermann; M Stahl; E F Stange
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

Review 2.  Histamine H₄ receptors in the gastrointestinal tract.

Authors:  A Deiteren; J G De Man; P A Pelckmans; B Y De Winter
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

3.  Claudin-2 as a mediator of leaky gut barrier during intestinal inflammation.

Authors:  J Luettig; R Rosenthal; C Barmeyer; J D Schulzke
Journal:  Tissue Barriers       Date:  2015-04-03

4.  Cell recovery during segmental intestinal perfusion in healthy subjects and patients with Crohn's disease.

Authors:  O Ahrenstedt; F Knutson; L Knutson; M Krog; O Sjöberg; R Hällgren
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

Review 5.  Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation.

Authors:  Ashkan Farhadi; Jeremy-Z Fields; Ali Keshavarzian
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

6.  Plasma histamine levels (H) during adjunctive H1-receptor antagonist treatment with loratadine in patients with active inflammatory bowel disease (IBD).

Authors:  M Raithel; A Nägel; Y Zopf; Th deRossi; Ch Stengel; A Hagel; J Kressel; E G Hahn; P Konturek
Journal:  Inflamm Res       Date:  2010-03       Impact factor: 4.575

7.  Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls.

Authors:  S C Bischoff; J Grabowsky; M P Manns
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

8.  Mast cell mediated ion transport in intestine from patients with and without inflammatory bowel disease.

Authors:  S E Crowe; G K Luthra; M H Perdue
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

9.  Role of histamine in a rat model of colitis.

Authors:  C M Gelbmann; K E Barrett
Journal:  Inflamm Res       Date:  1995-09       Impact factor: 4.575

10.  Relationship between mast cells and the colitis with relapse induced by trinitrobenzesulphonic acid in Wistar rats.

Authors:  Ana Carolina Luchini; Déborah Mara Costa de Oliveira; Cláudia Helena Pellizzon; Luiz Claudio Di Stasi; José Carlos Gomes
Journal:  Mediators Inflamm       Date:  2009-05-11       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.